EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism

Olga Buneeva, Alexei Medvedev

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26031248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Olga Buneeva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Chemistry, 10 Pogodinskaya Street, 119121 Moscow, Russia. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Parkinsonian Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program for Basic Research in the Russian Federation for a long-term period (2021-2030).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoamine oxidase inhibitors are widely used for the symptomatic treatment of Parkinson’s disease (PD). They demonstrate antiparkinsonian activity in different toxin-based models induced by 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and pesticides (rotenone and paraquat). In some models, such as MPTP-induced PD, MAO inhibitors prevent the formation of the neurotoxin MPP+ from the protoxin MPTP. Regardless of the toxin’s nature, potent MAO inhibitors prevent dopamine loss reduction, the formation of hydrogen peroxide, hydrogen peroxide signaling, and the accumulation of hydrogen peroxide-derived reactive oxygen species responsible for the development of oxidative stress. It becomes increasingly clear that some metabolites of MAO inhibitors (e.g., the rasagiline metabolite 1-R-aminoindan) possess their own bio-pharmacological activities unrelated to the parent compound. In addition, various MAO inhibitors exhibit multitarget action, in which MAO-independent effects prevail. This opens new prospects in the development of novel therapeutics based on simultaneous actions on several prospective targets for the therapy of PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoamine Oxidase InhibitorsParkinsonian DisordersHumansAnimalsMonoamine OxidaseOxidative StressDisease Models, AnimalParkinson DiseaseReactive Oxygen Species

Stichwörter der Autor:innen

Parkinson’s diseasemonoamine oxidasemonoamine oxidase inhibitorstoxin-based models

Substanzen

Monoamine Oxidase InhibitorsMonoamine OxidaseReactive Oxygen Species

Autor:innen und Institutionen

  • Institute of Biomedical Chemistry, 10 Pogodinskaya Street, 119121 Moscow, Russia.

Förderung

  • Program for Basic Research in the Russian Federation for a long-term period (2021-2030)

Zitieren

APA

Buneeva, O., & Medvedev, A. (2025). Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031248

Vancouver

Buneeva O, Medvedev A. Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031248

BibTeX
@article{Buneeva2025,
  author = {Buneeva, Olga and Medvedev, Alexei},
  title = {Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26031248}
}
Kostenlos starten →